Table 1.
Disease | Model(s) | IDO1 ko | IDO2 ko | Inhibitors |
---|---|---|---|---|
Arthritis | KRN | no effect (13, 14) | reduced (11, 13, 14) | reduced (18, 24, 61) |
CIA | Increased (22) | n.d. | reduced (24, 26) increased (22, 23) no effect (24, 25) |
|
JIA | no effect (20) | n.d. | n.d. | |
Psoriasis | IMQ | no effect (32) | increased (32) | n.d. |
Multiple Sclerosis | EAE | increased (27, 28) | no effect (28) | increased (29, 30) reduced (31) |
Lupus | Nba2 | no effect (33) | n.d. | no effect (33) |
MRL/lpr | n.d. | n.d. | reduced (34) increased (19) |
|
Allergy/Asthma | CHS | reduced (12) | reduced (11, 12) | n.d. |
Ag-induced asthma | reduced (37) | n.d. | n.d. | |
Immunization | T Independent Type I | increased (9) no effect (14) |
no effect (14) | n.d. |
T Independent Type II | increased (9) no effect (14) |
reduced (14) | n.d. | |
T Dependent | no effect (9, 14) | no effect (14) | n.d. | |
Influenza | PR8 | increased CD8 (38) no effect on Ab (14, 38) |
reduced (14) | n.d. |
Endotoxic Shock | LPS | reduced (39) | increased (40) | n.d. |
Aspergillosis | A. fumigatus | reduced (41) | n.d. | n.d. |
The inflammatory response in the listed models is indicated as increased, reduced,neither increased nor decreased (no effect), or not determined (n.d.).